Patents by Inventor Edward M. Rudnic

Edward M. Rudnic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020004070
    Abstract: An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: February 22, 2001
    Publication date: January 10, 2002
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20020004499
    Abstract: An antibiotic product for delivering at least two different antibiotics that is comprised of three dosage forms with different release profiles with each antibiotic being present in at least one of the dosage forms.
    Type: Application
    Filed: February 23, 2001
    Publication date: January 10, 2002
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20010055613
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Application
    Filed: October 21, 1998
    Publication date: December 27, 2001
    Inventors: BETH A. BURNSIDE, XIAODI GUO, KIMBERLY FISKE, RICHARD A. COUCH, RONG-KUN CHANG, DONALD J. TREACY, CHARLOTTE M. MCGUINNESS, EDWARD M. RUDNIC
  • Publication number: 20010048944
    Abstract: An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Type: Application
    Filed: February 22, 2001
    Publication date: December 6, 2001
    Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
  • Publication number: 20010046984
    Abstract: Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. In a preferred embodiment, release from the second, third and fourth dosage forms is initiated after the component released from the immediately previous form reaches Cmax.
    Type: Application
    Filed: February 23, 2001
    Publication date: November 29, 2001
    Inventor: Edward M. Rudnic
  • Patent number: 6322819
    Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
    Type: Grant
    Filed: October 21, 1998
    Date of Patent: November 27, 2001
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte McGuinness, Edward M. Rudnic
  • Patent number: 6284276
    Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semipermeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: September 4, 2001
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
  • Publication number: 20010006650
    Abstract: Disclosed is a beadlet comprising (i) a hydrophobic long chain fatty acid or ester material; (ii) a surfactant; and (iii) of a therapeutic agent which in admixture form a solid solution at room temperature. The hydrophobic material preferably has a melting point of about 40 to about 100° C., and is most preferably glyceryl behenate. The surfactant is preferably a polyglycolyzed glyceride, polyoxyethylene sorbate, ethylene or propylene block copolymer or combinations thereof, and is most preferably polyoxyethylene 20 sorbitan monolaurate.
    Type: Application
    Filed: September 18, 1998
    Publication date: July 5, 2001
    Inventors: BETH A. BURNSIDE, CHARLOTTE M. MCGUINNESS, EDWARD M. RUDNIC, RICHARD A. COUCH, XIAODI GUO, ALEXANDER K. TUSTIAN
  • Patent number: 6110498
    Abstract: An osmotic drug delivery system, preferably in tablet form, which dispenses a therapeutic agent having limited water solubility in solubilized form. The delivery system comprises a core that is free of swellable polymers and comprises nonswelling solubilizing agents and wicking agents. The solubilized therapeutic agent is delivered through a passageway in the semipermeable coating of the tablet.
    Type: Grant
    Filed: October 22, 1997
    Date of Patent: August 29, 2000
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
  • Patent number: 5912013
    Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: June 15, 1999
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, George W. Belendiuk, John McCarty, Sandra Wassink, Richard A. Couch
  • Patent number: 5897876
    Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: April 27, 1999
    Assignee: Shire Laboratories Inc.
    Inventors: Edward M. Rudnic, John A. McCarty, George W. Belendiuk, deceased, Beth A. Burnside, Charlotte M. McGuinness, Krystyna Belendiuk
  • Patent number: 5883103
    Abstract: A pharmaceutical preparation for oral acyclovir delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with acyclovir is incorporated into a pharmaceutical carrier suitable for oral delivery.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 16, 1999
    Assignee: Shire Laboratories Inc.
    Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk
  • Patent number: 5824638
    Abstract: A pharmaceutical preparation for oral insulin delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with insulin is incorporated into a pharmaceutical carrier suitable for oral delivery.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: October 20, 1998
    Assignee: Shire Laboratories, Inc.
    Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk, deceased
  • Patent number: 5484608
    Abstract: A sustained-release pharmaceutical composition comprising a highly soluble pharmaceutical agent, such as selegiline, in a pharmaceutical carrier comprising a hydrophilic polymer dispersed in a hydrophobic matrix. A hydrophilic microenvironment is created in a hydrophobic matrix by incorporating hydrophilic polymers within a hydrophobic matrix. Optionally, a binder, preferably a polyhydroxylated compound, ca also be added.
    Type: Grant
    Filed: March 28, 1994
    Date of Patent: January 16, 1996
    Assignee: Pharmavene, Inc.
    Inventors: Edward M. Rudnic, John A. McCarty, George W. Belenduik
  • Patent number: 5447729
    Abstract: A pharmaceutical preparation including a pharmaceutical agent incorporated into particles comprising (i) a core formed from a hydrophilic material, a hydrophobic material or a hydrophobic emulsion or dispersion and (ii) an alternating sequence of hydrophilic/hydrophobic layers thereon such that there is a hydrophilic/hydrophobic interface between the core and each succeeding layer.
    Type: Grant
    Filed: April 7, 1994
    Date of Patent: September 5, 1995
    Assignee: PharmaVene, Inc.
    Inventors: George W. Belenduik, Edward M. Rudnic, John A. McCarty
  • Patent number: 5430021
    Abstract: A pharmaceutical preparation including a drug incorporated into hydrophobic particles comprised of long chain carboxylic acid or ester thereof or long chain alcohol, wherein the particles are incorporated into a unit dosage form and are individually coated with an enteric coating and/or the unit dosage form includes an enteric protective material.
    Type: Grant
    Filed: March 18, 1994
    Date of Patent: July 4, 1995
    Assignee: Pharmavene, Inc.
    Inventors: Edward M. Rudnic, John A. McCarty, George W. Belenduik
  • Patent number: 5326570
    Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: July 5, 1994
    Assignee: Pharmavene, Inc.
    Inventors: Edward M. Rudnic, George W. Belendiuk
  • Patent number: 5262165
    Abstract: A transdermal nitroglycerin patch exhibiting superior nitroglycerin skin penetrating characteristics comprising a percutaneous penetration enhancer is disclosed, wherein the penetration enhancer may be one or more of N-methyl-2-pyrrolidone, oleic acid, oleyl butanediol, linoleic acid, isopropyl linoleate, azone and alcohol. Also disclosed is a transdermal patch design comprising two concentric rings, wherein the concentrations of nitroglycerin and the permeability enhancer are varied.
    Type: Grant
    Filed: February 4, 1992
    Date of Patent: November 16, 1993
    Assignee: Schering Corporation
    Inventors: Sharad K. Govil, Edward M. Rudnic, Dale G. Sterner
  • Patent number: 5186930
    Abstract: Stable sustained release wax- and polymer-coated drug-ion exchange resin complexes especially useful in preparing oral suspensions are disclosed.
    Type: Grant
    Filed: December 19, 1990
    Date of Patent: February 16, 1993
    Assignee: Schering Corporation
    Inventors: Patricia W. Kogan, Edward M. Rudnic, Joel A. Sequeira, Imtiaz A. Chaudry
  • Patent number: 5035898
    Abstract: Pharmacuetical compositions for administering a combination of controlled release potassium chloride and immediately-released magnesium salt are disclosed.
    Type: Grant
    Filed: November 27, 1987
    Date of Patent: July 30, 1991
    Assignee: Schering Corporation
    Inventors: Richard R. Chang, Edward M. Rudnic